Get started
MarkJosamQuinones

Bullish View on Clovis Oncology

Long
MarkJosamQuinones  
NASDAQ:CLVS   None
Trend Analysis clovis CLVS
0
0
trendanalysis clovis clvs
Bullish view on Clovis Oncology as it breaks $30 price resistance.
CLVS jumped 13% last Wednesday as sales of its Rubraca drug used to treat ovarian cancer patients went up 33% compared to previous quarter.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.